Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.
Synairgen engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease and severe viral infections, as well as COVID-19. The company was founded by Donna E. Davies, Ratko Djukanovic, and Stephen T. Holgate in June 2003 and is headquartered in Southampton.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as advisor to Synairgen plc in this transaction.
CEO, Synairgen plc
Talk to the deal team
PartnerLondon, United Kingdom
Intergrin has raised financing provided by Kartesia
Intergrin has obtained a unitranche loan of approximately US$59 million to refinance existing debt and to further support the growth of different healthcare and well-being initiatives.Learn more
Simtel Team has raised US$3.5 million through an equity private placement on BSE
Simtel Team (SMTL), a Romanian engineering and technology company, has raised US$3.5 million through a private placement of shares on the ATS Market of Bucharest Stock Exchange. The offer was closed on the first day, being oversubscribed three times, with the investors placing orders for a total value of US$10.4 million. Following the successful conclusion of the private placement, the anticipated capitalization of the company is approximately US$22 million.Learn more
Earlypay (ASX:EPY) has raised funds
Earlypay (ASX:EPY) has raised US$14.5 million to fund a new trade finance product, while the company puts in place a new warehouse facility.Learn more